Walleye Trading’s Akcea Therapeutics Inc AKCA Stock Holding History

Walleye Trading’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,021	Closed	-$86K	–	4727
2019 Q1	$86K	Buy	+3,021	New	+$88K	﹤0.01%	3531

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Walleye Trading's AKCA Position: Q2 2019 in Review

Walleye Trading sold out of Akcea Therapeutics Inc (AKCA) in Q2 2019, closing a stake of 3,021 shares — an estimated $86K sold.

Walleye Trading first reported a position in AKCA in Q1 2019 and held it in 1 quarter. The position peaked at $86K in Q1 2019. 68 funds tracked by Wall St. Rank hold AKCA as of Q2 2019.

Walleye Trading reported no remaining Akcea Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
Walleye Trading sold 3,021 Akcea Therapeutics Inc shares in Q2 2019, an estimated $86K.
Walleye Trading first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 1 quarter.
Walleye Trading's Akcea Therapeutics Inc position peaked at $86K in Q1 2019.
68 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2019.

Based on Walleye Trading's 13F filing for Q2 2019, filed 14 Aug 2019.